Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519178 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-06873600 in People With Cancer
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT03519178 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 155 participants.
The verdict
NCT03519178, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer. People may be able to participate in this study if they have the following types of cancer: Hormone Receptor positive (HR+) breast cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer that is advanced or metastatic (spread to other parts of the body); triple negative breast cancer; epithelial ovarian cancer; fallopian tube cancer; or primary peritoneal cancer. All participants in this study will receive the study medicine by mouth, 1 to 2 times a day at home. The dose of the study medicine may be changed during the study. Some participants will also receive hormone therapy. The hormone therapy will be either letrozole by mouth once a day at home, or fulvestrant as a shot into the muscle. Fulvestrant will be given every two weeks at the study clinic for the first month, and then once a month after that. Participants will take part in this study for at least 7 to 8 months, depending on how they respond to the therapy. During this time participants will visit the study clinic once a week for the first 2 cycles and every cycle thereafter.
Interventions
- DRUG PF-06873600
- DRUG Endocrine Therapy 1
- DRUG Endocrine Therapy 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03519178
The ClinicalTrials.gov registry entry for NCT03519178 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-06873600 is the first listed.
NCT03519178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03519178 about?
NCT03519178 is a clinical study titled "A Study of PF-06873600 in People With Cancer". The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer. People may be able to participate in this study if they have the following types of cancer: Hormone Receptor positive (HR+) bre...
What is the current status of trial NCT03519178?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2018-03-07. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT03519178?
The interventions under investigation include: PF-06873600 (DRUG), Endocrine Therapy 1 (DRUG), Endocrine Therapy 2 (DRUG).
Who is sponsoring clinical trial NCT03519178?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.